Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Daclizumab for relapsing remitting multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
ALSUntangled No. 8: Low dose naltrexone for ALS.
Application of fullerenes in nanomedicine: an update.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Pages